The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To test whether simvastatin has an additional anti-inflammatory effects on p38 MAPK, a signaling molecule for inflammation in inhaled steroid-treated asthmatics.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Anti-Inflammatory Agents; Simvastatin

Criteria

Inclusion Criteria:

• mild-to-moderate persistent asthmatics

• FEV1 = OR > 50% of predicted

Exclusion Criteria:

• Previous history of renal disease or serum creatinine is more than 2 mg/dl.

• Previous history of liver disease.

• Pregnancy or lactation.

• Are already receiving or are known to be allergic to statins or to have developed myositis.

• Have an asthma exacerbation requiring treatment with oral corticosteroids during the 3 months prior to the commencement of study entry.

• Being treated with immunosuppressive agents.

• Unwilling to cooperate the study.